Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Company Deals PIC

Typewriter Therapeutics Raises USD 56 Million Series A to Advance TPRT RNA Gene Insertion Platform for In Vivo CAR-T and Liver Diseases

Fineline Cube Sep 4, 2026
Company Deals Drug PIC

Takeda and Belief BioMed End Xinjiuning Commercialization Partnership; Belief BioMed to Advance Gene Therapy Independently

Fineline Cube Sep 4, 2026
Company Deals Drug PIC

Keymed Biosciences Grants Aeira Exclusive Rights to Stapokibart Across 18 Southeast and Central Asia Markets, Securing High Double‑Digit Royalties

Fineline Cube Sep 3, 2026
Company Deals PIC

Medtronic Invests USD 700 Million in Cornerstone Robotics, Wins Distribution Rights for Sentire Endoscopic Surgical Robot Outside the U.S.

Fineline Cube Sep 3, 2026
Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Fineline Cube Sep 4, 2026
Policy / Regulatory

China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks

Fineline Cube Sep 4, 2026
Company Deals

VectorBuilder Partners with Sino Biological to Boost Global Biological Reagents Market

Fineline Cube Dec 15, 2023

VectorBuilder, a genetic engineering specialist based in Guangzhou and nurtured by the state-owned Guangzhou Industrial...

Company Deals

CATUG Biotechnology Partners with Carcell Biopharma to Advance Nucleic Acid Drug Development

Fineline Cube Dec 15, 2023

CATUG Biotechnology (Suzhou) Co., Ltd, a Chinese biotechnology company, has entered into a partnership with...

Company Drug

Sino Biopharmaceutical Submits Market Approval Application for Recombinant Coagulation Factor VIIa

Fineline Cube Dec 15, 2023

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the...

Company Drug

Lepu Biotechnology’s Pancreatic Cancer Drug Earns Orphan Drug Status from FDA

Fineline Cube Dec 15, 2023

Lepu Biotechnology Co., Ltd (HKG: 2157), a Chinese pharmaceutical company, has announced that it has...

Company Deals

AbelZeta Pharma Expands Janssen Partnership to Include Commercial Rights in China

Fineline Cube Dec 15, 2023

AbelZeta Pharma Inc., a Sino-US biotechnology company with operations in Rockville, Maryland, and Shanghai, China,...

Company Drug

AbbVie and Genmab’s Epcoritamab Shows Promising Results in Follicular Lymphoma Study

Fineline Cube Dec 14, 2023

AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) have presented Phase I/II clinical data for their...

Company Drug

Amgen’s Tarlatamab Receives FDA Priority Review for Advanced Small Cell Lung Cancer Treatment

Fineline Cube Dec 14, 2023

The US Food and Drug Administration (FDA) has granted priority review status to Amgen (NASDAQ:...

Company

Pfizer’s $43 Billion Seagen Acquisition Closes Amid Lackluster 2024 Forecast

Fineline Cube Dec 14, 2023

Pfizer Inc. (NYSE: PFE) has secured all necessary regulatory approvals to finalize its $43 billion...

Company Deals

Fosun Pharmaceutical and Insightec Form JV to Bring MRgFUS Brain Therapy to China

Fineline Cube Dec 14, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced plans to establish a joint...

Policy / Regulatory

Jiangsu Initiates Sunshine Procurement Round for Medical Consumables with 46 Products

Fineline Cube Dec 14, 2023

The Jiangsu Public Resource Trading Platform has announced a new round of sunshine online procurement...

Company Deals

HighTide Therapeutics Inc. Raises USD 25 Million in Hong Kong IPO

Fineline Cube Dec 14, 2023

HighTide Therapeutics Inc., (HKG: 2511) a China-based biopharmaceutical company, has successfully completed an initial public...

Company Medical Device

MicroPort MedBot’s R-ONE Vascular Intervention Robot Approved by China’s NMPA

Fineline Cube Dec 14, 2023

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received market...

Company Drug

Eisai and BioArctic Set December Launch for Alzheimer’s Drug Leqembi in Japan

Fineline Cube Dec 14, 2023

Eisai (TYO: 4523) and BioArctic (STO: BIOA-B) have announced the launch of Leqembi (lecanemab) in...

Company Drug

Abbisko Therapeutics’ Pimicotinib Earns FDA Fast-Track Status for TGCT Treatment

Fineline Cube Dec 14, 2023

Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology firm, has announced that its colony...

Policy / Regulatory

China’s 2023 NRDL Expands Coverage with 126 New Drugs, Aims for Savings and Accessibility

Fineline Cube Dec 13, 2023

The National Healthcare Security Administration (NHSA) has released the finalized National Reimbursement Drug List (NRDL)...

Company Deals

AstraZeneca Acquires Icosavax to Boost Infectious Disease Pipeline with VLP Vaccine Technology

Fineline Cube Dec 13, 2023

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has announced the acquisition of US vaccines specialist...

Company Drug

BMS Presents Promising Golcadomide Trial Results for Non-Hodgkin Lymphomas

Fineline Cube Dec 13, 2023

Bristol Myers Squibb (BMS; NYSE: BMY) has presented results from Phase I and Phase I/II...

Policy / Regulatory

Hong Kong Aims for “First-Level Approvals” with New Drug Regulatory Institution

Fineline Cube Dec 13, 2023

Hong Kong is taking steps to establish a drug regulatory institution that will permit “first-level...

Company Medical Device

Sino Medical Sciences Secures Market Approvals in Hong Kong, China, and Malaysia for Medical Devices

Fineline Cube Dec 13, 2023

China-based Sino Medical Sciences Technology Inc., (SHA: 688108) has announced receiving market approvals for two...

Company Drug

J&J’s Carvykti Demonstrates Extended Time to Symptom Worsening in Multiple Myeloma Patients

Fineline Cube Dec 13, 2023

Johnson & Johnson (J&J; NYSE: JNJ) has released data from a Phase III study showing...

Posts pagination

1 … 480 481 482 … 716

Recent updates

  • MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China
  • China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks
  • Trinomab’s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo
  • Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib
  • Betta’s Ensartinib Wins NMPA Approval for Third Indication as Adjuvant Therapy in ALK-Positive NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

MSD’s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China

Policy / Regulatory

China’s 2026 NHSA Drug Negotiations Open Sept 5 with Parallel Commercial Insurance Innovative Drug Catalog Talks

Company Drug

Trinomab’s Retavibart Wins NMPA Priority Approval as RSV Prevention Monoclonal Antibody Xinduotuo

Company Deals

Xuanzhu Biopharmaceutical Signs Thailand Commercial Agreement with Innobic and ZaoAn for Bireociclib

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.